瑞舒伐他汀对2型糖尿病合并急性心肌梗死临床应用价值

目的 探讨瑞舒伐他汀对2型糖尿病合并急性心肌梗死（AMI）患者临床应用价值.方法 选择我院2型糖尿病合并AMI的患者98例,随机分为A组和B组各49例.2组均给予糖尿病饮食、控制血糖等常规治疗,B组在常规治疗基础上加用瑞舒伐他钙汀片,用药剂量根据患者的个体差异进行调整,常用剂量在10～40mg,1次/d,口服,疗程6个月.以酶联免疫吸附法对血清内脂素、IL-6、TNF-α水平进行测定;免疫比浊法测定C反应蛋白（hs-CRP）.结果 治疗后A、B组各指标均较治疗前有改善（P〈0.01）;B组除Fins外,FBG、Homa-IR、内脂素、IL-6、TNF-α及hs-CRP水平均明显低于A组（P〈0.05）结论 瑞舒伐他汀可降低2型糖尿病合并AMI患者内脂素及炎性因子水平,且改善2型糖尿病合并AMI患者血糖代谢,改善患者的治疗及预后.

Clinical application value of rosuvastatin in the treatment of type 2 diabetes with acute myocardial infarction

Objective To explore the clinical application value of rosuvastatin in the treatment of type 2 diabetes with acute myocardial infarction （AMI）. Methods 98 cases of type 2 diabetes patients with AMI were randomly divided into group A and group B, each of 49 cases. Both groups were received routine treatment such as diabetic diet, controlling blood glu- cose,while the group B was given rosuvastatin for treatment based on the routine treatment. The dosage of rosuvastatin was ad- justed according to the individual difference of the patient, the commonly dose was 10 - 40mg, l/d, oral, and treatment for 6 months. The serum visfatin, IL-6, TNF-α levels were measured with the method of enzyme - linked immunosorbent assay. The c response protein （hs-CRP） was measured with immunoturbidimetry. Results Comparing with before treatment, each index of both groups improved after treatment, the difference was significant （ P 〈 0.01 ）. Besides Fins, the FBG,Homa-IR,visfatin,IL- 6 ,TNF-α and hs-CRP levels of group B were lower than those of the group A, the difference was significant （ P 〈 0.05 ）. Con- clusion Rosuvastatin can reduce the visfatin and inflammatory factor levels of type 2 diabetes patients with AMI, and improve the metabolism of glucose and prognosis of them.